Print this page Email this page | Users Online: 286
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
REVIEW ARTICLE
Year : 2016  |  Volume : 7  |  Issue : 4  |  Page : 235-241

Cellular and molecular aspects at invasive tumor front in oral squamous cell carcinoma (Part-II)


Department of Oral Pathology and Microbiology, Government Dental College and Hospital, Nagpur, Maharashtra, India

Date of Web Publication13-Dec-2016

Correspondence Address:
Rekha Bhaskar Chaudhari
Department of Oral Pathology and Microbiology, Government Dental College and Hospital, Nagpur - 444 003, Maharashtra
India
Login to access the Email id


DOI: 10.4103/0976-433X.195635

Rights and Permissions
  Abstract 

Oral squamous cell carcinoma (OSCC) is the most prevalent malignant cancer in the oral cavity. Despite considerable advances in diagnostic and therapeutic field, its prognosis remains poor. Grading by histopathological features does not influence prognosis until deeply invasive margins are evaluated by pathologists. The most invasive part of malignant tumor reflects disturbance in molecular mechanism, alteration in gene expression that controls cell differentiation, growth, death (apoptosis) as well as interactions between cancer cells and stromal components that may lead to the formation of oncofetal extracellular matrix, enabling tumor cell phenotype transition and migration. In recent years, analysis of cell proliferation, DNA content, and epithelial-mesenchymal transition (EMT) phenomenon has been used in an attempt to identify new prognostic indicators. Great interest is also shown in matrix metalloproteinase which plays a key role in invasion and metastasis. This review focuses on altered pathways in OSCC at gene expression and protein level, role of proteinases and EMT phenomenon in tumor progression, invasion, and metastasis with respect to invasive tumor front.

Keywords: Genetic markers, matrix metalloproteinases, molecular factors, oral squamous cell carcinoma, tumor budding and epithelial-mesenchymal transition


How to cite this article:
Chaudhari RB. Cellular and molecular aspects at invasive tumor front in oral squamous cell carcinoma (Part-II). SRM J Res Dent Sci 2016;7:235-41

How to cite this URL:
Chaudhari RB. Cellular and molecular aspects at invasive tumor front in oral squamous cell carcinoma (Part-II). SRM J Res Dent Sci [serial online] 2016 [cited 2019 Jun 16];7:235-41. Available from: http://www.srmjrds.in/text.asp?2016/7/4/235/195635


  Introduction Top


Oral squamous cell carcinoma (OSCC) is one of the most common malignancies. Despite diagnostic and therapeutic progress in oncology, during the past decade, it has fairly onerous prognosis. Its morphological and functional characteristics indicate the biological aggressiveness, reflected by alteration and mutation that alter cell-matrix interaction and cell signal pathways. [1] Progress of OSCC primarily depends on clinicopathological factors that however has shown limited predictive value. Prognostic information is essential for evaluation and optimal treatment of patients.

Oral carcinogenesis is a multistep process which involves precancerous lesions, invasion and metastasis. Degradation of cell cycle, proliferation of malignant cells results in loss of control mechanism that ensures normal function of tissue. Transformed neoplastic cells determine biologic behavior of the tumor. [2] The activated tissue microenvironment at the advancing tumor front seems to provide appropriate stimuli for triggering molecular alterations. Invasive tumor front (ITF) is considered as a "biologic horizon" of the tumor with high prognostic significance. It also represents the area where cancer cells are bathed in the host milieu of oxygen and other nutrients from angiogenesis, enabling them to grow actively. [3] Tumor cells have the property to invade and spread through surrounding tissues. Cellular and molecular mechanism that illustrates this complex biology includes - overexpression of extracellular matrix (ECM) degrading enzymes, cytoskeleton protein interplay, abnormal DNA contents, proliferation, and epithelial-mesenchymal transition (EMT).

The aim of the present article is to review the current knowledge on prognostic value of cellular and genetic/molecular expressions at ITF. Published scientific data were collected and scanned. Articles pertaining to studies undertaken to find genetic alterations, abnormal DNA contents, overexpression of ECM-degrading enzymes, cytoskeleton protein interplay, angiogenesis, and cell motility/migration (EMT and tumor budding) with respect to ITF were identified and selected.


  Matrix Metalloproteinases Top


Invasion and metastasis of cancer cells are a complex multistep processes involving cooperation of multiple proteolytic enzymes, secreted by tumor or host cells. [4] Matrix metalloproteinases (MMPs) are the most important ECM-degrading enzymes. Activation of MMP cascade is accompanied by altered expression of many adhesion molecules by transformed cells. Trafficking of neoplastic cells through ECM is necessary for invasive activity. [5] Surrounding tumor stroma is an integral player in this process. Tumor cells are capable of utilizing MMPs, produced by stromal cells, indicating the active role of stroma in tumor invasion. [6] Because ECM shows complex structure combined action of several MMPs is crucial for degradation of ECM components which acts as a barrier. [5] Tumor cells frequently overexpress MMP, and this has been shown to be correlated with invasive capacity, metastatic potential, and poor prognosis. Marked expression of MMP-1 (collagenase), MMP-2 (gelatinase), MMP-8, and MMP-9 at ITF has been demonstrated to be related with cell motility and recurrence and poor survival, [4],[5],[7],[8],[9] whereas MT1-MMP (MMP-14) expression was shown to be inversely associated with MMP-2 and MMP-9, suggesting a sequential action of these proteases in different moments of invasive process. [5] In addition, localization of MMP-7 (matrilysin), exclusively observed in cancer cells, at invasive front has been shown. MMP-7 mediated Fas-L cleavage provides a mechanism to evade apoptosis and thereby facilitating cell survival and progression. [5] Thus, MMPs are key mediators of cancer invasion. [8] Expression of MMP-2 and -9 (gelatinases) has not been shown to be correlated with any clinicopathological or prognostic variables by Mäkinen et al. [7] On the contrary, Kurahara et al. [9] showed that expressions of MMP-2 and -9 correlated significantly with nodal status in OSCC. A correlation of nuclear immunoexpression of MMP-13 with invasive depth, tumor size, and disease-specific survival in oral tongue squamous cell carcinoma (OTSCC) has been detected by Mäkinen et al. [7] They suggested that MMP-13 may be regarded as a prognostic biomarker in OTSCC. MMP-7 combined with other markers may be used to predict the metastatic potential of OSCC, [5] whereas MMP-2 is a marker of poor survival. [4]


  Tissue Inhibitor of Metalloproteinases Top


Activity of MMPs is regulated by tissue inhibitor of metalloproteinases (TIMPs). It seems that concerted action of MMPs and TIMPS is involved in ECM remodeling in OSCC. [8] Overproduction of MMP appears to be important for metastasis than production of TIMPs in vivo. [9] However, many authors have demonstrated high levels of TIMPs, correlating with local invasion and metastasis. [4],[8],[10],[11] Overexpression of TIMPs is characteristic in head and neck squamous cell carcinoma (HNSCC). O-Charoenrat et al. [11] explained elevated expressions of TIMP-1 in HNSCC by the growth promoting activity of TIMPs on a variety of cell types or the induction of TIMPs by secreted MMPs, from tumor-host interaction in the extracellular milieu. Among the best known and widely studied are TIMP-1, -2, -3 and have long been associated with metastasis. [4],[6],[8],[9] A significant association of MT1-MMP with TIMP2 has been shown by de Vicente et al. [5] and Katayama et al. [10] Role of these factors for activation of pro-MMP-2 is explained by the mechanism of cell-mediated MMP-2 activation in which pro-MMP-2 binds to TIMP-2 in combination with MT1-MMP on cell surface forming a tertiary complex. The pro-MMP-2 in this complex is activated by adjacent MT1-MMP and activated MMP-2 degrades ECM components that correlate well with OSCC progression. [10] Singh et al. [12] showed correlation between MMP-2, TIMP-1, and TIMP-2 levels with lymph node involvement, stage, and differentiation. In addition, Ondruschka et al. [4] detected marked TIMP-2 expression at invasive front. Further Kurahara et al. [10] reported that marked TIMP-2 expression might be considered as the most valuable indicator in identifying patient's risk for poor prognosis. However, reports on in vivo involvement of MMPs and TIMPs in oral cancer are still contradictory. Evidence suggests that MMPs and their physiological tissue inhibitor TIMPs play a causal role in oral cancer progression. [12]


  Cytogenetic Changes Top


Biologic behavior of oral cancer is considered to reflect genetic alterations in cancer cells. These alterations include reduced expression or overexpression of proteins. Genetic instability is the intrinsic characteristic of malignant tumor. The genes that are altered include p53, cyclin D1 (CCD1), epithelial growth factor receptor (EGFR), signal transduction, vascular endothelial growth factor (VEGF) as well as other molecules. These alterations affect cell cycle regulation, cellular differentiation, proliferation, death, DNA repair, and cellular immunity. [2] Among these, p53 is the most notable. [13],[14],[15] Inactivation of tumor suppressor gene (TSG) can occur via epigenetic or genetic mechanism. [14] The interactions between activation of oncogenes and loss of function of TSGs drive uncontrolled growth and invasion. Tumorigenic alterations involve activation of oncogene (genetic instability due to impairment of DNA repair) and inactivation of TSGs, exemplified by the loss of heterozygosity (LOH), deletion, and epigenetically through DNA methylation or chromatin remodeling. [14]

Kato et al. [15] and Kato et al. [16] measured p53 labeling index (LI) at ITF in OSCC and reported a significant correlation of overexpression of p53 LI with clinical outcome. High p53 LI at ITF was associated with worse prognosis. However, Piffkò et al. [13] could not demonstrate biological significance of p53 alteration at ITF. In OSCC, p53 is mutated, resulting in loss of p53 control of cell cycle progression and apoptosis. Thus, aberrant cellular expression of p53 is a good prognostic biomarker of stage and malignant vigor of cancer and predictor of tumorigenesis. Verma et al. [14] demonstrated a linear increase in p53 expression at ITF through varying grades in OSCC, suggesting it to be independent of histological grade.

p21 protein (WAF1/CIP1) is a cyclin-dependent kinase inhibitor which is one target of the transcriptionally active p53 and mediates cell cycle arrest after DNA damage. Horta et al. [17] observed overexpressions of p53 and p21 WAF1/CIP1 at the invasive front of lip SCC with no correlation between their expressions at ITF or at whole tumor and reinforced that ITF is the most important area for tumor behavior and further supports that p53-independent mechanisms are involved in the expression of p21 (WAF1/CIP1). Further, overexpression of p53 as well as decreased intensity of p63 immunostaining has been shown to be associated with metastases and correlated with poor outcome. [18]

Noguchi et al. [19] examined prognostic significance of cancer cells with abnormal DNA content at ITF in OSCC and observed that high DNA content of tumor cells implies bad prognosis for clinical outcome or survival and considered it as powerful independent prognostic factor, influencing survival. LOH and microsatellite instability (MSI) have been documented as important events in OSCC and were studied by Wang et al. [20] in invasive front/center, superficial part, and stromal cells. Statistically high frequency of LOH and MSI at chromosomal loci TP53 and RP56 at invasive front than at other region was observed. It has been postulated that relationship between histological grading and genotypes of OSCC exists. Chromosomal aberrations such as deletion, amplification, and structural rearrangement are hallmark of malignancy. There is allelic loss/imbalance during progression from premalignant to malignant phenotype. Yamamoto et al. [21] demonstrated that allelic loss in 2q, 3p, and 21q region was associated with OSCC progression and correlated it with worse prognosis, particularly regarding 2q. Partridge et al. [22] observed a correlation between AI/LOH and high recurrence rate in OSCC patients and stated that it could be a better prognostic factor than tumor-node-metastasis (TNM) staging system.


  Cyclin D1 Top


It is a key regulator of cell proliferation and exerts its function in late G1 phase. It is frequently expressed in OSCC. [23] A positive CCD1 expression has been shown in high-grade OSCC by Lam et al. CCD1 expression appears to have a predictive value for the prognosis of the patients with lower TNM stage oral carcinoma. [23]


  Epithelial Growth Factor Receptor Top


EGFR is a transmembrane glycoprotein and tyrosine kinase receptor, expressed in HNSCC. Mutation can result in abnormal activation of EGFR that promotes cell proliferation and inhibits apoptosis. [24] A statistically significant correlation between increased EGFR and tumor front score, and with advanced lymph node involvement in OSCC has been shown by Bánkfalvi et al. [25] and Gröbe et al., [24] respectively. This stresses the importance of ITF in the molecular cross-talk between tumor and host. This molecular change is accompanied by invasive growth of the tumor and poor survival of the patients. Increased expression of EGFR has been linked to advanced OSCC and to poor prognosis and suggested as supplementary tool for prognostic assessment and predicting metastasis [25] and locoregional control in OSCC patients. [24]


  Proliferative Activity of Cancer Cells at Invasive Tumor Front Top


OSCC is a disease resulting from genetic damage leading to uncontrolled cell proliferation of damaged cells. [26] Cell proliferations are defined as increase in a number of cells resulting from completion of cell cycle. [27] Tumor cell proliferative activity is believed to indicate the degree of aggressiveness of the tumor. [28] Control of this important biologic process is believed to be lost in cancer. ITF might have putative biological significance because of accumulation of abnormal cells. [29] The two most common IHC markers used to study cell proliferation are - Ki-67 and proliferative cell nuclear antigen (PCNA).


  KI-67 Top


It is a nonhistone nuclear protein. It is expressed in all active phases of cell cycle (G1, S, G2, and mitosis), but it is absent from resting cells (G0) and reaches its peak in G2 and M phases. [30] Various studies have shown positive correlation between Ki-67 expression at ITF and OSCC grading. [26],[28],[31],[32] A significant positive relationship between cell proliferation (using Ki-67 LI) at ITF and number of prognostic (clinical stage and tumor thickness) and risk factors (smoking, alcohol consumption) in human OSCC has been shown by Tumuluri et al. [26] Whereas a strong relationship of Ki-67 LI with histological grading in OSCC was reported by other investigators. [15],[28],[29] Further p53 expression was shown to be significantly correlated with that of Ki-67 in OSCC, suggesting that altered p53 overexpression may promote increased cell proliferation. [31] High Ki-67 labeling values may indicate biologic malignancy with high proliferative activity. [15] Kurokawa et al. [28] further suggested that high values of Ki-67 and p53 positive status may be related in turn to the progression and metastatic spread in OSCC. All these results emphasize the potential of Ki-67 as prognostic marker for OSCC. [31]


  Proliferative Cell Nuclear Antigen Top


It is the most representative proliferative marker that plays an important role in DNA replication, chromatin remodeling, and DNA repair. Alteration in PCNA activity is common genetic event in various cancers including OSCC. Kato et al. [15] recorded high expression of PCNA at ITF and correlated it with the abnormal proliferative activity. It can be used as an independent predictor of histologic grade, recurrence rate, and prognosis. [15]


  Apoptosis Regulated Proteins Top


Kato et al. [33] evaluated prognostic value of interrelation of opposing apoptotic proteins ( Bcl-2 and Bax) expression at invasive front of OSCC and concluded that Bax expression was found to be the strongest independent prognostic parameter. The Bax (Pro-apoptotic protein) binds to antiapoptotic Bcl-2, leading to inactivation of anti apoptotic function of Bcl-2. Patients with negative Bcl-2 expression and + Bax expression had a significant better prognosis. Results of their study suggested that Bax is a better prognostic marker than Bcl-2 in OSCC.


  Phosphatase and Tensin Homolog Top


Phosphatase and tensin homolog (PTEN) is a TSG that regulates cell physiology such as division, differentiation, apoptosis, migration, and adhesion. Immunohistochemical study of aggressive OSCC with high score malignancy has not demonstrated PTEN expression at invasive edge. At ITF − ve immunoreactivity for PTEN suggested relation of PTEN to histologic pattern and biological behavior. Inactivation or absence of PTEN results in increased accumulation of phosphatidylinositol triphosphate which increases phosphatidylinositol-3 kinase (PI3K) activity, contributing to cell survival and antiapoptotic stimuli. [34]


  Hepatocyte Growth Factor Top


Hepatocyte growth factor (HGF), also known a scatter factor, is a pleiotropic growth factor with many diverse biological effects such as cell proliferation, migration, tumor angiogenesis, invasion, and metastasis. These are mediated via interaction with a transmembrane tyrosine kinase receptor - c-met protein. A significant correlation of high expression of HGF LI and c-met LI in ITF with clinical parameters (large tumor size and regional lymph node metastasis) has been shown by Chen et al. [35] HGF can activate extracellular signal-related kinases (ERK), the PI3K/AKT or nuclear factor-κβ signaling pathway, thus inhibiting apoptosis and thereby inducing tumor growth and promote cancer metastasis, through production of MMPs. Thus, HGF LI in ITF and c-met can be a good biomarker for prognosis of OSCC. [35]


  Vascular Endothelial Growth Factor Top


Angiogenesis and lymphangiogenesis are well known to be essential for tumor growth and metastasis. VEGF secreted by cancer cells and stromal cells proved to play a major role in tumor angiogenesis. [36] VEGF family members include -A, -B, -C, and -D. Among these, VEGF-A promotes angiogenesis, whereas VEGF-C is a potent inducer of lymphangiogenesis, leading to tumor cell dissemination. [37] Overexpression of VEGF-A and -C has been shown to be related to lymph node metastasis by Yanase et al. [37] In contrast, downregulation of VEGF-C in deep area near invasive front has been shown by Ohno et al., [36] indicating poor lymphangiogenesis. VEGF-C may be considered as predictor factor of OSCC outcome. [37]


  Prognostic Value of Signaling Molecules - Phosphorylated Extracellular Signal-Regulated Kinases (P-Extracellular Signal Related Kinase1/2) and Cyclo-Oxygenase-2 Top


Interaction between tumor cells and neighboring stromal components at ITF is of crucial importance for tumor behavior. Søland et al. [38] investigated prognostic value of P-ERK1/2 and cyclooxygenase (COX)-2 at ITF. Patients with tumor showing P-ERK1/2 staining and upregulation or absence of COX-2 reported to be unfavorable for clinical outcome and poor prognosis. Activation of intracellular signaling cascade involving Ras, ERK1/2 can promote cell proliferation, invasion, and prognosis in HNSCC. Overexpression of COX-2 and resultant synthesis of prostaglandins such as PGE2 can affect several processes such as angiogenesis, invasion, and proliferation during tumorigenesis. Because of diverse expressions, COX-2 was not considered of prognostic significance at ITF or in other tumor area. These molecules are of established importance in cell proliferation and tumor development. [38]


  Basic Fibroblast Growth Factor Top


Basic fibroblast growth factor (bFGF) is a cytokine, closely associated with activated fibroblasts and mediates the interaction between cancer cells and host tissue stroma. Increased prevalence of bFGF expression, FGF receptor-1 expression at invasive front has been demonstrated to be linked to mode of invasion and prognosis in OSCC. bFGF promotes production of cancer cells proteinases and enhances their invasive ability. It is reported that bFGF exerts influences upon fibroblasts to produce HGF, transforming growth factor (TGF)-β, and MMP-2 which are associated with tumor invasion. Furthermore, bFGF also initiates angiogenesis actively by interacting with various endothelial cell receptors. Proliferative activity of tumor has been correlated with the expression of bFGF in OSCC. [39]


  Aldehyde Dehydrogenase-1 Top


Aldehyde dehydrogenase (ALDH)-1 is considered as putative marker of highly tumorigenic cells (i.e., cancer stem-like cells) in HNSCC. Hildebrand et al. [40] evaluated pattern of ALDH expression in the center and ITF region of the tumor. ALDH-1 immunostaining indicated more aggressive behavior and was positively related with clinical parameter (tumor size and regional metastasis) and histopathological grading and tumor progression in HNSCC. ALDH-1 positive neoplastic cells have proliferative ability similar to that observed in stem cells. The lack of similar association in tumor cells may be due to cell hierarchy with less aggressive biological behavior. [40]


  Transforming growth factor-β Top


TGF-β1 is thought to be involved in cell attachment to ECM; thereby influencing invasion and lymph node metastasis of cancer cells. TGF-β1 transforms OSCC cell lines into mesenchymal phenotype. It has been demonstrated that TGF-β signaling induces EMT by forming activated transcription complexes that directly inhibits E-cad gene activity. Subsequently, loss of E-cad and cell-cell adhesion allows oral cancer cells to become motile and invasive. It is also considered as potent inducer of oral cancer progression. [41]


  Tumor Budding and Epithelial-Mesenchymal Transition Top


Recently, a number of unique features of cancer cells located at ITF have been recognized including tumor budding and EMT that are associated with increased cell motility and invasiveness. Tumor budding is a morphological marker of tumor invasion [42] and is defined as the presence of either isolated single cell or small cluster (up to 4) scattered in stroma at ITF, and high intensity tumor budding has been demonstrated as adverse prognostic factor in patients with tongue SCC. [43] Budding represents two malignant features - discohesion and active invasion. [43] Association of Ln-5 expression with high intensity of tumor budding and with high density of stromal MF has been shown to suggests permissive environment for invasion in OSCC. [42] Wang et al. [43] observed reduction in E-cadherin in ITF and budding cells which is accompanied by increase in vimentin expression. Microscopically, tumor cells in ITF and tumor buds exhibit distinct switch in morphological features including dedifferentiation and loss of cell-cell adhesion. This fibroblast-like morphological appearance is characteristic of the cell undergoing EMT. [43]

EMT is defined as a process during which epithelial cells downregulate specific adhesive proteins (e.g., E-cadherins), induce mesenchymal proteins (e.g., vimentin), and acquire migrating properties. [44] Differential expression of E-cadherin/β catenin [45] and demonstration of vimentin-positive cells at ITF, expressing Laminin-5/γ2chain mRNA, [46] implicated EMT origin [46] for cells in ITF. The PI3K/AKT pathway is directly linked to EMT-like phenotype in human OSCC cell lines. AKT activation induces the decrease of proteins-E-cadherin/β-catenin and triggers the expression of mesenchymal marker such as vimentin. It also changes cellular morphology, leads to loss of cellular polarization and decrease in cell-ECM adhesion and production of MMPs. Thus, EMT causes an increase in cell motility, invasion and is associated with more aggressive behavior of cancer cells. [47] EMT is considered to be crucial for the development of an invasive and metastatic phenotype potential. However, carcinoma cell phenotype conversion at OSCC invasive front is poorly understood. [44] Furthermore, Yang et al. [48] demonstrated EMT positive immunoreactions with tumor satellite formation, located at ITF, indicating a link between EMT and tumor invasive front and suggesting a cross-talk between tumor cells and tumor microenvironment. Thus, EMT may be considered a new signal from invasive front.


  Conclusion and Perspectives Top


Several cellular and molecular characteristic at ITF have an impact on progress of OSCC and may be used as valuable tool for predicting OSCC patient outcome. Genetic expression profile may offer greater accuracy in diagnosis and prognosis. MMPs are important group of proteolytic enzymes used by cancer cells to degrade ECM. Molecular factors modulate cell behavior and enhance progression by regulating angiogenesis, migration, proliferation, and invasion. Advances in cancer research have provided new knowledge about cellular/molecular mechanism in the complex biology of tumor progression and invasion. Several molecular factors have been strongly correlated with outcome showing promising pathways for future development of more effective prognostic system and anticancer treatment therapies. Diagnostic and prognostic value of genetic and other molecular factors has been emphasized. Understanding of cellular and molecular events at ITF is of paramount importance with respect to improving prognosis.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Williams HK. Molecular pathogenesis of oral squamous carcinoma. Mol Pathol 2000;53:165-72.  Back to cited text no. 1
    
2.
Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett 2014;8:7-11.  Back to cited text no. 2
    
3.
Upile T, Jeriges W, Johal O, Lew-Gor S, Sudhoff H. The deleterious nature of the invasive front and dysplasia at margins in the long term outcome from surgical treatment of squamous cell carcinoma of the head and neck. Head Oncol 2012;4:72.  Back to cited text no. 3
    
4.
Ondruschka C, Buhtz P, Motsch C, Freigang B, Schneider-Stock R, Roessner A, et al. Prognostic value of MMP-2, -9 and TIMP-1,-2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract 2002;198:509-15.  Back to cited text no. 4
    
5.
de Vicente JC, Lequerica-Fernández P, Santamaría J, Fresno MF. Expression of MMP-7 and MT1-MMP in oral squamous cell carcinoma as predictive indicator for tumor invasion and prognosis. J Oral Pathol Med 2007;36:415-24.  Back to cited text no. 5
    
6.
Thomas GT, Lewis MP, Speight PM. Matrix metalloproteinases and oral cancer. Oral Oncol 1999;35:227-33.  Back to cited text no. 6
    
7.
Mäkinen LK, Häyry V, Atula T, Haglund C, Keski-Säntti H, Leivo I, et al. Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J Oral Pathol Med 2012;41:394-9.  Back to cited text no. 7
    
8.
Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, et al. Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis. Br J Cancer 1998;77:2239-45.  Back to cited text no. 8
    
9.
Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: Correlations with tumor invasion and metastasis. Head Neck 1999;21:627-38.  Back to cited text no. 9
    
10.
Katayama A, Bandoh N, Kishibe K, Takahara M, Ogino T, Nonaka S, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 2004;10:634-40.  Back to cited text no. 10
    
11.
O-Charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:813-20.  Back to cited text no. 11
    
12.
Singh RD, Haridas N, Patel JB, Shah FD, Shukla SN, Shah PM, et al. Matrix metalloproteinases and their inhibitors: Correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem 2010;25:250-9.  Back to cited text no. 12
    
13.
Piffkò J, Bànkfalvi A, Tory K, Füzesi L, Bryne M, Ofner D, et al. Molecular assessment of p53 abnormalities at the invasive front of oral squamous cell carcinomas. Head Neck 1998;20:8-15.  Back to cited text no. 13
    
14.
Verma R, Singh A, Jaiswal R, Chandra A, Verma R, Tak J. Association of Ki-67 antigen and p53 protein at invasive tumor front of oral squamous cell carcinoma. Indian J Pathol Microbiol 2014;57:553-7.  Back to cited text no. 14
[PUBMED]  Medknow Journal  
15.
Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Okamune A, Sugiura S, et al. Expression form of p53 and PCNA at the invasive front in oral squamous cell carcinoma: Correlation with clinicopathological features and prognosis. J Oral Pathol Med 2011;40:693-8.  Back to cited text no. 15
    
16.
Kato K, Kawashiri S, Tanaka A, Noguchi N, Nakaya H, Hase T, et al. Predictive value of measuring p53 labeling index at the invasive front of oral squamous cell carcinomas. Pathol Oncol Res 2008;14:57-61.  Back to cited text no. 16
    
17.
Horta MC, de Assis LA, de Souza AF, de Araújo VC, Gomez RS, Aguiar MC. p53 and p21WAF1/CIP1 overexpression at the invasive front of lower lip squamous cell carcinoma. J Oral Pathol Med 2007;36:88-92.  Back to cited text no. 17
    
18.
de Oliveira LR, Ribeiro-Silva A, Zucoloto S. Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma. J Oral Pathol Med 2007;36:191-7.  Back to cited text no. 18
    
19.
Noguchi M, Kinjyo H, Kohama GI, Nakamori K. Invasive front in oral squamous cell carcinoma: Image and flow cytometric analysis with clinicopathologic correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:682-7.  Back to cited text no. 19
    
20.
Wang XH, Fan MW, Sun ZJ, Chen XM, Wang L, Li Y. The TP53 and RPS6 alterations at the invasive tumor front, center and stroma of oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi 2007;42:140-3.  Back to cited text no. 20
    
21.
Yamamoto N, Mizoe JE, Numasawa H, Tsujii H, Shibahara T, Noma H. Allelic loss on chromosomes 2q, 3p and 21q: Possibly a poor prognostic factor in oral squamous cell carcinoma. Oral Oncol 2003;39:796-805.  Back to cited text no. 21
    
22.
Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Lee G, Phillips E, et al. The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer. Br J Cancer 1999;79:1821-7.  Back to cited text no. 22
    
23.
Lam KY, Ng IO, Yuen AP, Kwong DL, Wei W. Cyclin D1 expression in oral squamous cell carcinomas: Clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med 2000;29:167-72.  Back to cited text no. 23
    
24.
Gröbe A, Eichhorn W, Fraederich M, Kluwe L, Vashist Y, Wikner J, et al. Immunohistochemical and FISH analysis of EGFR and its prognostic value in patients with oral squamous cell carcinoma. J Oral Pathol Med 2014;43:205-10.  Back to cited text no. 24
    
25.
Bánkfalvi A, Krassort M, Végh A, Felszeghy E, Piffkó J. Deranged expression of the E-cadherin/beta-catenin complex and the epidermal growth factor receptor in the clinical evolution and progression of oral squamous cell carcinomas. J Oral Pathol Med 2002;31:450-7.  Back to cited text no. 25
    
26.
Tumuluri V, Thomas GA, Fraser IS. The relationship of proliferating cell density at the invasive tumour front with prognostic and risk factors in human oral squamous cell carcinoma. J Oral Pathol Med 2004;33:204-8.  Back to cited text no. 26
    
27.
Pardee AB. G1 events and regulation of cell proliferation. Science 1989;246:603-8.  Back to cited text no. 27
    
28.
Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Tomoyose T, et al. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma. J Oral Pathol Med 2005;34:602-7.  Back to cited text no. 28
    
29.
Piffkó J, Bánkfalvi A, Ofner D, Kusch F, Böcker W, Joos U, et al. In situ assessment of cell proliferation at the invasive front of oral squamous cell carcinomas. Virchows Arch 1996;429:229-34.  Back to cited text no. 29
    
30.
Sasaki K, Murakami T, Kawasaki M, Takahashi M. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-84.  Back to cited text no. 30
    
31.
Iamaroon A, Khemaleelakul U, Pongsiriwet S, Pintong J. Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med 2004;33:30-6.  Back to cited text no. 31
    
32.
Tumuluri V, Thomas GA, Fraser IS. Analysis of the Ki-67 antigen at the invasive tumour front of human oral squamous cell carcinoma. J Oral Pathol Med 2002;31:598-604.  Back to cited text no. 32
    
33.
Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Yamamoto E. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J Oral Pathol Med 2008;37:364-71.  Back to cited text no. 33
    
34.
Squarize CH, Castilho RM, Santos Pinto D Jr. Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J Oral Pathol Med 2002;31:379-84.  Back to cited text no. 34
    
35.
Chen YS, Wang JT, Chang YF, Liu BY, Wang YP, Sun A, et al. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 2004;33:209-17.  Back to cited text no. 35
    
36.
Ohno F, Nakanishi H, Abe A, Seki Y, Kinoshita A, Hasegawa Y, et al. Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: An analysis in comparison with angiogenesis. J Oral Pathol Med 2007;36:281-9.  Back to cited text no. 36
    
37.
Yanase M, Kato K, Yoshizawa K, Noguchi N, Kitahara H, Nakamura H. Prognostic value of vascular endothelial growth factors A and C in oral squamous cell carcinoma. J Oral Pathol Med 2014;43:514-20.  Back to cited text no. 37
    
38.
Søland TM, Husvik C, Koppang HS, Boysen M, Sandvik L, Clausen OP, et al. A study of phosphorylated ERK1/2 and COX-2 in early stage (T1-T2) oral squamous cell carcinomas. J Oral Pathol Med 2008;37:535-42.  Back to cited text no. 38
    
39.
Hase T, Kawashiri S, Tanaka A, Nozaki S, Noguchi N, Kato K, et al. Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma. J Oral Pathol Med 2006;35:136-9.  Back to cited text no. 39
    
40.
Hildebrand LC, Carvalho AL, Lauxen IS, Nör JE, Cerski CT, Sant'Ana Filho M. Spatial distribution of cancer stem cells in head and neck squamous cell carcinomas. J Oral Pathol Med 2014;43:499-506.  Back to cited text no. 40
    
41.
Ahmed S, Liu CC. TGF-β signaling promotes epithelial-mesenchymal transition during oral squamous cell carcinoma. J Oral Pathol Med 2006;35:4.  Back to cited text no. 41
    
42.
Marangon Junior H, Rocha VN, Leite CF, de Aguiar MC, Souza PE, Horta MC. Laminin-5 gamma 2 chain expression is associated with intensity of tumor budding and density of stromal myofibroblasts in oral squamous cell carcinoma. J Oral Pathol Med 2014;43:199-204.  Back to cited text no. 42
    
43.
Wang C, Huang H, Huang Z, Wang A, Chen X, Huang L, et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med 2011;40:545-51.  Back to cited text no. 43
    
44.
Richter P, Umbreit C, Franz M, Berndt A, Grimm S, Uecker A, et al. EGF/TGFß1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332. J Oral Pathol Med 2011;40:46-54.  Back to cited text no. 44
    
45.
Wang X, Zhang J, Fan M, Zhou Q, Deng H, Aisharif MJ, et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: Immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:547-54.  Back to cited text no. 45
    
46.
Franz M, Richter P, Geyer C, Hansen T, Acuña LD, Hyckel P, et al. Mesenchymal cells contribute to the synthesis and deposition of the laminin-5 gamma2 chain in the invasive front of oral squamous cell carcinoma. J Mol Histol 2007;38:183-90.  Back to cited text no. 46
    
47.
Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-8.  Back to cited text no. 47
    
48.
Yang J, Weinberg RA. Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-29.  Back to cited text no. 48
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Matrix Metallopr...
Tissue Inhibitor...
Cytogenetic Changes
Cyclin D1
Epithelial Growt...
Proliferative Ac...
KI-67
Proliferative Ce...
Apoptosis Regula...
Phosphatase and ...
Hepatocyte Growt...
Vascular Endothe...
Basic Fibroblast...
Aldehyde Dehydro...
Transforming gro...
Tumor Budding an...
Conclusion and P...
Prognostic Value...
References

 Article Access Statistics
    Viewed769    
    Printed3    
    Emailed0    
    PDF Downloaded195    
    Comments [Add]    

Recommend this journal